Diaphragmatic Breathing Reduces Belching and Proton Pump Inhibitor Refractory Gastroesophageal Reflux Symptoms (original) (raw)

Abstract

BACKGROUND & AIMS: In patients with gastroesophageal reflux disease (GERD) and excessive belching, most belches are supragastric, and can induce reflux episodes and worsen GERD. Supragastric belching (SGB) might be reduced with diaphragmatic breathing exercises. We investigated whether diaphragmatic breathing therapy is effective in reducing belching and proton pump inhibitor (PPI)-refractory gastroesophageal reflux symptoms. METHODS: We performed a prospective study of 36 consecutive patients with GERD refractory to PPI therapy and a belching visual analogue scale (VAS) score of 6 or more, seen at a gastroenterology clinic at a tertiary hospital in Singapore from April 2015 through October 2016. Patients underwent high-resolution manometry and 24-hour pH-impedance studies while they were off PPIs. Fifteen patients were placed on a standardized diaphragmatic breathing exercise protocol (treatment group) and completed questionnaires at baseline, after diaphragmatic breathing therapy, and 4 months after the therapy ended. Twenty-one patients were placed on a waitlist (control subjects), completed the same questionnaires with an additional questionnaire after their waitlist period, and eventually received diaphragmatic breathing therapy. The primary outcome was reduction in belching VAS by 50% or more after treatment. Secondary outcomes included GERD symptoms (evaluated using the reflux disease questionnaire) and quality of life (QoL) scores, determined from the Reflux-Qual Short Form and EuroQoL-VAS. RESULTS: Nine of the 15 patients in the treatment group (60%) and none of the 21 control subjects achieved the primary outcome (P < .001). In the treatment group, the mean belching VAS score decreased from 7.1-1.5 at baseline to 3.5-2.0 after diaphragmatic breathing therapy; in the control group, the mean VAS score was 7.6-1.1 at baseline and 7.4-1.3 after the waitlist period. Eighty percent of patients in the treatment group significantly reduced belching frequency compared with 19% in control subjects (P [ .001). Treatment significantly reduced symptoms of GERD (the mean reflux disease questionnaire score decreased by 12.2 in the treatment group and 3.1 in the control group; P [ .01). The treatment significantly increased QoL scores (the mean Reflux-Qual Short Form score increased by 15.4 in the treatment group and 5.2 in the control group; P [ .04) and mean EuroQoL-VAS scores (15.7 increase in treatment group and 2.4 decrease in the control group). These changes were sustained at 4 months after treatment. In the end, 20 of the 36 patients who received diaphragmatic breathing therapy (55.6%), all with excessive SGB, achieved the primary outcome. CONCLUSIONS: In a prospective study, we found a standardized protocol for diaphragmatic breathing to reduce belching and PPI-refractory gastroesophageal reflux symptoms, and increase QoL in patients with PPI-refractory GERD with belching-especially those with excessive SGB.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (29)

  1. Sifrim D, Zerbib F. Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors. Gut 2012; 61:1340-1354.
  2. Klauser AG, Schindlbeck NE, Müller-Lissner SA. Symptoms in gastro-oesophageal reflux disease. Lancet 1990;335:205-208.
  3. Hemmink GJM, Bredenoord AJ, Weusten BL, et al. Supragastric belching in patients with reflux symptoms. Am J Gastroenterol 2009;104:1992-1997.
  4. Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology 2006;130:1466-1479.
  5. Kessing BF, Bredenoord AJ, Velosa M, et al. Supragastric belches are the main determinants of troublesome belching symptoms in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2012;35:1073-1079.
  6. Koukias N, Woodland P, Yazaki E, et al. Supragastric belching: prevalence and association with gastroesophageal reflux dis- ease and esophageal hypomotility. J Neurogastroenterol Motil 2015;21:398-403.
  7. Kessing BF, Bredenoord AJ, Smout AJPM. The pathophysi- ology, diagnosis and treatment of excessive belching symp- toms. Am J Gastroenterol 2014;109:1196-1203.
  8. Kahrilas PJ, Miner P, Johanson J, et al. Efficacy of rabeprazole in the treatment of symptomatic gastroesophageal reflux dis- ease. Dig Dis Sci 2005;5:2009-2018.
  9. Miner P, Orr W, Filippone J, et al. Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo- controlled trial. Am J Gastroenterol 2002;97:1332-1339.
  10. Gerson LB, Kahrilas PJ, Fass R. Insights into gastroesophageal reflux disease-associated dyspeptic symptoms. Clin Gastro- enterol Hepatol 2011;9:824-833.
  11. Kriengkirakul C, Patcharatrakul T, Gonlachanvit S. The therapeutic and diagnostic value of 2-week high dose proton pump inhibitor treatment in overlapping non-erosive gastro- esophageal reflux disease and functional dyspepsia patients. J Neurogastroenterol Motil 2012;18:174-180.
  12. Hemmink GJM, Ten Cate L, Bredenoord AJ, et al. Speech therapy in patients with excessive supragastric belching: a pilot study. Neurogastroenterol Motil 2010;22:24-30.
  13. Vakil N, Van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101:1900-1920.
  14. Shaw M, Dent J, Beebe T, et al. The Reflux Disease Question- naire: a measure for assessment of treatment response in clinical trials. Health Qual Life Outcomes 2008;6:31.
  15. Shaw MJ, Talley NJ, Beebe TJ, et al. Initial validation of a diagnostic questionnaire for gastroesophageal reflux disease. Am J Gastroenterol 2001;96:52-57.
  16. Amouretti M, Nalet B, Robaszkiewicz M, et al. Validation of the short-form REFLUX-QUAL (RQS), a gastro-esophageal reflux disease (GERD) specific quality of life questionnaire. Gastro- enterol Clin Biol 2005;29:793-801.
  17. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001;33:337-343.
  18. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-370.
  19. Kroenke K, Spitzer RL, Williams JB. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. Psychosom Med 2002;64:258-266.
  20. Bredenoord AJ, Weusten BLAM, Sifrim D, et al. Aerophagia, gastric, and supragastric belching: a study using intra- luminal electrical impedance monitoring. Gut 2004; 53:1561-1565.
  21. Flaisher GF. The use of suggestion and behavioral methods in the treatment of aerophagia: two case reports. Child Fam Behav Ther 1994;16:24-32.
  22. Cigrang JA. Behavioral treatment of chronic belching due to aerophagia in a normal adult. Behav Modif 2006; 30:341-351.
  23. Katzka DA. Simple office-based behavioral approach to patients with chronic belching. Dis Esophagus 2013;26:570-573.
  24. Kessing BF, Bredenoord AJ, Smout AJPM. Mechanisms of gastric and supragastric belching: a study using concurrent high-resolution manometry and impedance monitoring. Neuro- gastroenterol Motil 2012;24:573-579.
  25. Eherer AJ, Netolitzky F, Hogenauer C, et al. Positive effect of abdominal breathing exercise on gastroesophageal reflux disease: a randomized, controlled study. Am J Gastroenterol 2012;107:372-378.
  26. Bredenoord AJ, Weusten BLAM, Timmer R, et al. Psychological factors affect the frequency of belching in patients with aerophagia. Am J Gastroenterol 2006;101:2777-2781.
  27. Chen Y-F, Huang X-Y, Chien C-H, et al. The effectiveness of diaphragmatic breathing relaxation training for reducing anxiety. Perspect Psychiatr Care 2017;53:329-336.
  28. Freedberg DE, Kim LS, Yang Y-X. The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association. Gastroenterology 2017;152:706-715.
  29. Cunningham JA, Kypri K, McCambridge J. Exploratory randomized controlled trial evaluating the impact of a waiting list control design. BMC Med Res Methodol 2013;13:150.